Andrew Brockmyre, MD
Family Medicine · Bristol, TNNPI 1013911890
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2019 at $6,551 and has fallen 70.7% since, to $1,920 in 2025. Among family medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 629 payments — averaging $28.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- Novo Nordisk AS$2K
- Eli Lilly$2K
- Pfizer$2K
- Novo Nordisk$1K
- Bayer$1K
- plus $6K from 44 others
Across 1,600 payments — averaging $1100.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$707K
- Merck$409K
- Eli Lilly$387K
- Pfizer$184K
- AbbVie$41K
- AstraZeneca$21K
- plus $12K from 3 others
What the payments were for
- Speaking & faculty fees$450%
- Travel & lodging$7,42041%
- Food & beverage$10,28458%
- Education$1311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUVIVIQ$110
How this compares
$17,881 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $168,194 |
| OzempicSemaglutide | 69 | $92,792 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $65,702 |
| TrulicityDulaglutide | 39 | $42,714 |
| MounjaroTirzepatide | 33 | $36,714 |
| MyrbetriqMirabegron | 41 | $32,247 |
| WegovySemaglutide | 23 | $31,921 |
| JanuviaSitagliptin Phosphate | 27 | $28,692 |
| JardianceEmpagliflozin | 20 | $28,194 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $25,953 |
| EntrestoSacubitril/Valsartan | 18 | $25,899 |
| Spiriva RespimatTiotropium Bromide | 26 | $24,234 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $20,392 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $20,302 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $19,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,524 | $168,194206 claims |
| Novo NordiskOzempic, Wegovy | $1,388 | $124,71392 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $808 | $105,844149 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $290 | $79,42872 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $51 | $60,94265 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $175 | $32,99429 claims |
| Astellas Pharma US IncMyrbetriq | $495 | $32,24741 claims |
| MerckJanuvia | $4,141 | $28,69227 claims |
| NovartisEntresto | $94 | $25,89918 claims |
| AbbVieLinzess | $886 | $7,87915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Bristol
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
- Meredith SchweitzerAntioch$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.